



## CMV-Tetramer TEST

**Ready-to-use Staining Kit for monitoring CMV-specific T cells  
in whole blood**

Greater safety for patients with progressive CMV infections

Fast | Safe | Complete | CE-certified | Flow cytometric analysis of whole blood

# CMV-Tetramer TEST

## Monitoring CMV-specific T cells

Progressive CMV infections pose a major threat to transplant recipients. CD8 T cells are considered as the major player to control CMV viremia and sufficient levels of CMV-specific CD8 T cells are found to protect against CMV disease<sup>1,2</sup>.

Current assays based on PCR and antigen-detection are capable of analysing the viral burden and detect a CMV-reactivation, however, any immunoreactivity against CMV cannot be assessed.

The CMV-Tetramer Test provides for the first time a ready-to-use kit to quantify the number of CMV-specific CD8 T cells, thus helping the clinician to assess patients with high risk to develop CMV disease.

### Assay Features:

- Standardized and CE-certified ready-to-use staining kit (performance time about 2h)
- Direct analysis of whole blood

- Highly specific and sensitive detection of CMV-specific CD8 T cells with tetramers
- Combination of well characterized immunodominant CMV peptides and HLA-types (A1, A2, B7)
- Determination of the absolute numbers of CMV-specific CD8 T cells and the percentage CD4 and CD8 T cells.
- Kit contains all necessary compounds including a negative control
- Easy and economic procedure based on flow cytometry achieving quick results at low costs with high accuracy and precision

### Expected benefits of monitoring the CMV-specific CD8 T cell number<sup>1-5</sup>:

- The test allows the clinician to assess the immune status of the patient and identifies patients at risk for CMV disease.
- It helps the clinician to reduce the amount of toxic and expensive antiviral drugs in the treatment of patients with a good CMV-specific immune response.



### References:

1) Gratama & Cornelissen, Clin. Appl. Immun. Rev. 2001; 2) Moss & Khan, Hum. Immun. 2004; 3) Cwynarski et al. Blood 2001; 4) Gratama et al. Blood 2001; 5) Gratama et al., Cytometry B Clin. Cytom. 2008

For more information please contact us

### Dr. Jürgen Walter

Head of Tetramer Production

Phone: + 49 6221 9105-720 | e-mail: tetramer@glycotope-bt.com

Glycotope Biotechnology GmbH | Czernyring 22 | D-69115 Heidelberg | Germany | www.glycotope-bt.com